This CE activity will highlight recent advances in the management of relapsing and progressive multiple sclerosis (MS) as presented at the Advanced Curriculum of Multiple Sclerosis 2020 annual meeting in West Palm Beach, FL. The expert faculty, Dr. Amit Bar-Or, will review the latest updates in imaging tools to improve patient diagnosis as well as discuss recent data for the management of multiple sclerosis to improve patient-specific treatment plans. Dr. Bar-Or will relay best practices for creating individualized treatment plans for patients with MS. Upon completion of this activity, learners will gain insight into current standards for improving outcomes and quality of life in patients with multiple sclerosis.
Neurologists, internists, PCPs, and other healthcare professionals, including nurses, NPs, PAs, and pharmacists who care for patients with MS
- Updates in Disease Biomarkers & Imaging Tools for Patient Monitoring and Diagnosis
- Analyzing Appropriate Modalities for Optimal Individualized Treatment of Relapsing Multiple Sclerosis
- Analyzing Appropriate Modalities for Optimal Individualized Treatment of Progressive Multiple Sclerosis
- Discuss biomarkers of the disease and the latest updates in imaging tools to diagnose and monitor patients with multiple sclerosis.
- Develop patient-specific treatment plans using an analysis of recent data of appropriate modalities for the management of relapsing multiple sclerosis.
- Create individualized treatment plans using an analysis of recent data of appropriate modalities for the management of progressive multiple sclerosis.
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson President’s Distinguished Professor
Director, Center for Neuroinflammation and Experimental Therapeutics
Chief, Multiple Sclerosis Division, Department of Neurology
Physician and Research Scientist, Children’s Hospital of Philadelphia
Perelman School of Medicine, University of Pennsylvania
Professor Adjunct, Montreal Neurological institute, McGill University
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Amit Bar-Or, MD, FRCPC||Consultant/Advisor: Atara Biotherapeutics; Biogen Idec; Celgene Corporation/Receptos Inc.; Genentech Inc./Roche Ltd.; MAPI-Pharma Ltd.; Medimmune Pharma B.V.; Merck & Co. Inc./EMD Serono Inc.; Novartis International AG; Sanofi-Genzyme Corporation
Speakers Bureau: Atara Biotherapeutics; Biogen Idec; Celgene Corporation/Receptos Inc.; Genentech Inc./Roche Ltd.; MAPI-Pharma Ltd.; Medimmune Pharma B.V.; Merck & Co. Inc./EMD Serono Inc.; Novartis International AG; Sanofi-Genzyme Corporation
Grant/Research Support: Celgene Corporation/Receptos Inc.; Genentech Inc./Roche Ltd.; Merck & Co. Inc./EMD Serono Inc.; Novartis International AG; Sanofi-Genzyme Corporation
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Devon Dietzel hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Celgene Corporation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].